Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (CAT#: GTTS-WQ1786MR)

This product GTTS-WQ1786MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_000417.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3559
UniProt ID	P01589

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1786MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ12011MR	IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	MM-302
GTTS-WQ5461MR	IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	CDB-1
GTTS-WQ3784MR	IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	BAY-86-6150
GTTS-WQ4703MR	IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	BMS-986168
GTTS-WQ15567MR	IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	UNII-FFX71LCS5T
GTTS-WQ106MR	IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	1121B
GTTS-WQ4646MR	IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	BMS-986036
GTTS-WQ4893MR	IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	BYM338

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST